The Food and Drug
Administration has approved Allergan's RESTASIS MULTIDOSE, its bottled version of
RESTASIS, both of which are free of preservatives.
RESTASIS was released in 2003 and is the only FDA-approved form of treatment for
Chronic Dry Eye. It is available in prescription form.
"RESTASIS MULTIDOSE will be an important addition to
the Allergan family of dry eye products, as it will enable healthcare providers
to offer an additional option for those patients who may prefer their eye drops
in a multi-dose bottle versus single-use vials," Advanced Vision Care
cornea and cataract specialist Dr. Neda Shamie said.
RESTASIS was developed to help patients with the production
of tears, which can be decreased by inflammation that is linked to Chronic Dry
Eye. RESTASIS MULTIDOSE will be available in a bottle holding multiple doses
for the same price as RESTASIS and uses less plastic than the single-use vials.
"RESTASIS MULTIDOSE exemplifies Allergan's commitment
to innovation and customer responsiveness," Allergan Chief Research and
Development Officer David Nicholson said. "Through our Open
Science model, we drive to deliver advancements in highly engineered
developments, such as the new multi-dose bottle."
FDA approves Allergan’s RESTASIS MULTIDOSE
Alerts Sign-up